Sten Randahl Sörensen
Chief Executive Officer chez CERENO SCIENTIFIC AB
Profil
Sten Randahl Sörensen is currently the Chief Executive Officer & Director at Cereno Scientific AB, the Executive Chairman at SARomics Biostructures AB, and the Director at SynAct Pharma AB.
Previously, he served as the Chairman at AcuCort AB and Stayble Therapeutics AB.
He also worked as the Director-Secondary Prevention Products Marketing at AstraZeneca AB.
From 1987 to 1995, he was the Head-International Marketing Operations at Monsanto Crop Sciences Sweden AB.
Mr. Sörensen completed his undergraduate degree at the University of Lund.
Postes actifs de Sten Randahl Sörensen
| Sociétés | Poste | Début |
|---|---|---|
| CERENO SCIENTIFIC AB | Chief Executive Officer | 01/09/2015 |
| SYNACT PHARMA AB | Director/Board Member | 20/03/2024 |
SARomics Biostructures AB
 SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Chairman | 01/01/2013 |
Anciens postes connus de Sten Randahl Sörensen
| Sociétés | Poste | Fin |
|---|---|---|
| Monsanto Crop Sciences Sweden AB | Sales & Marketing | 01/01/1995 |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Sales & Marketing | - |
| STAYBLE THERAPEUTICS AB | Chairman | - |
| ACUCORT AB | Chairman | - |
Formation de Sten Randahl Sörensen
| University of Lund | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ACUCORT AB | Health Technology |
| SYNACT PHARMA AB | Health Technology |
| CERENO SCIENTIFIC AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| Entreprise privées | 3 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| Monsanto Crop Sciences Sweden AB | |
SARomics Biostructures AB
SARomics Biostructures AB BiotechnologyHealth Technology SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden. | Health Technology |
